• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌患者 PD-L1/PD-L2 表达的抗原呈递细胞的临床和预后价值。

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.

机构信息

Independent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.

I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-081 Lublin, Poland.

出版信息

Int J Mol Sci. 2021 Oct 26;22(21):11563. doi: 10.3390/ijms222111563.

DOI:10.3390/ijms222111563
PMID:34768993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8583913/
Abstract

The latest literature demonstrates the predominant role of the programmed cell death axis (PD-1/PD-L1/PD-L2) in ovarian cancer (OC) pathogenesis. However, data concerning this issue is ambiguous. Our research aimed to evaluate the clinical importance of PD-L1/PD-L2 expression in OC environments. We evaluated the role of PD-L1/PD-L2 in OC patients ( = 53). The analysis was performed via flow cytometry on myeloid (mDCs) and plasmacytoid dendritic cells (pDCs) and monocytes/macrophages (MO/MA) in peripheral blood, peritoneal fluid (PF), and tumor tissue (TT). The data were correlated with clinicopathological characteristics and prognosis of OC patients. The concentration of soluble PD-L1 (sPD-L1) and PD-1 in the plasma and PF were determined by ELISA. We established an accumulation of PD-L1/PD-L2 mDCs, pDCs, and MA in the tumor microenvironment. We showed an elevated level of sPD-L1 in the PF of OC patients in comparison to plasma and healthy subjects. sPD-L1 levels in PF showed a positive relationship with Ca125 concentration. Moreover, we established an association between higher sPD-L1 levels in PF and shorter survival of OC patients. An accumulation of PD-L1/PD-L2 mDCs, pDCs, and MA in the TT and high sPD-L1 levels in PF could represent the hallmark of immune regulation in OC patients.

摘要

最新文献表明,程序性死亡受体 1/配体 1/配体 2(PD-1/PD-L1/PD-L2)轴在卵巢癌(OC)发病机制中起主要作用。然而,关于这个问题的数据是模糊的。我们的研究旨在评估 PD-L1/PD-L2 在 OC 环境中的临床重要性。我们评估了 PD-L1/PD-L2 在 OC 患者(=53)中的作用。通过流式细胞术在外周血、腹腔液(PF)和肿瘤组织(TT)中的髓样树突状细胞(mDC)和浆细胞样树突状细胞(pDC)和单核细胞/巨噬细胞(MO/MA)上进行分析。将数据与 OC 患者的临床病理特征和预后相关联。通过 ELISA 测定血浆和 PF 中可溶性 PD-L1(sPD-L1)和 PD-1 的浓度。我们在肿瘤微环境中建立了 PD-L1/PD-L2 mDC、pDC 和 MA 的积累。我们发现 OC 患者 PF 中的 sPD-L1 水平高于血浆和健康受试者。PF 中的 sPD-L1 水平与 Ca125 浓度呈正相关。此外,我们还发现 PF 中较高的 sPD-L1 水平与 OC 患者的生存时间较短有关。TT 中 PD-L1/PD-L2 mDC、pDC 和 MA 的积累和 PF 中高 sPD-L1 水平可能代表 OC 患者免疫调节的特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/9fbb8b94f875/ijms-22-11563-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4f406d8761e1/ijms-22-11563-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/d6288fb9f109/ijms-22-11563-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f60f5a96e7fb/ijms-22-11563-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f8075c591ad6/ijms-22-11563-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4a4b2ea5ea3e/ijms-22-11563-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4f4df389e715/ijms-22-11563-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/dc805d3a5e7c/ijms-22-11563-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/981359a90a60/ijms-22-11563-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/5287897c3c31/ijms-22-11563-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/7544736356c8/ijms-22-11563-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f2eee1ce9bcd/ijms-22-11563-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/e7de96f7bb03/ijms-22-11563-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/9fbb8b94f875/ijms-22-11563-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4f406d8761e1/ijms-22-11563-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/d6288fb9f109/ijms-22-11563-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f60f5a96e7fb/ijms-22-11563-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f8075c591ad6/ijms-22-11563-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4a4b2ea5ea3e/ijms-22-11563-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/4f4df389e715/ijms-22-11563-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/dc805d3a5e7c/ijms-22-11563-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/981359a90a60/ijms-22-11563-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/5287897c3c31/ijms-22-11563-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/7544736356c8/ijms-22-11563-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/f2eee1ce9bcd/ijms-22-11563-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/e7de96f7bb03/ijms-22-11563-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c62e/8583913/9fbb8b94f875/ijms-22-11563-g013.jpg

相似文献

1
Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.卵巢癌患者 PD-L1/PD-L2 表达的抗原呈递细胞的临床和预后价值。
Int J Mol Sci. 2021 Oct 26;22(21):11563. doi: 10.3390/ijms222111563.
2
Prognostic and Clinical Value of Interleukin 6 and CD45CD14 Inflammatory Cells with PD-L1/PD-L2 Expression in Patients with Different Manifestation of Ovarian Cancer.不同临床表现卵巢癌患者中白细胞介素 6 和 CD45CD14 炎性细胞与 PD-L1/PD-L2 表达的预后和临床价值。
J Immunol Res. 2020 Sep 30;2020:1715064. doi: 10.1155/2020/1715064. eCollection 2020.
3
Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.PD-1/PD-L1/PD-L2 通路在子宫内膜异位症患者中的临床价值。
Int J Mol Sci. 2022 Oct 1;23(19):11607. doi: 10.3390/ijms231911607.
4
[Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].程序性细胞死亡蛋白1及其配体调节变应性鼻炎中的免疫平衡
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Apr 7;55(4):384-390. doi: 10.3760/cma.j.cn115330-20190618-00392.
5
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.在卵巢癌患者治疗前,循环血液中表达PD-L1的髓系来源抑制细胞(M-MDSCs)以及单核细胞/巨噬细胞的积累与可溶性PD-L1相关。
J Transl Med. 2020 Jun 1;18(1):220. doi: 10.1186/s12967-020-02389-7.
6
Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.淋巴恶性肿瘤中的可溶性程序性死亡蛋白 1(sPD-1)和可溶性程序性死亡配体 1 和 2(sPD-L1 和 sPD-L2)。
Eur J Haematol. 2021 Jul;107(1):81-91. doi: 10.1111/ejh.13621. Epub 2021 Apr 12.
7
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.Ras 相关结构域家族蛋白 1A 甲基化和 PD-L1 表达与卵巢癌的关系:一项 112 例回顾性研究。
Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:103-108. doi: 10.1016/j.ejogrb.2019.06.015. Epub 2019 Jun 13.
8
The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.PD-1/PD-Ls 在 IgG4 相关疾病发病机制中的作用。
Rheumatology (Oxford). 2022 Feb 2;61(2):815-825. doi: 10.1093/rheumatology/keab360.
9
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.程序性死亡-1配体1和2在皮肤鳞状细胞癌中的表达及其与肿瘤浸润树突状细胞的关系。
Clin Exp Immunol. 2017 Jun;188(3):420-429. doi: 10.1111/cei.12921. Epub 2017 Mar 12.
10
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.原发性中枢神经系统淋巴瘤中肿瘤微环境(包括肿瘤周围组织)中的 PD-L1 和 PD-L2 表达。
BMC Cancer. 2020 Apr 5;20(1):277. doi: 10.1186/s12885-020-06755-y.

引用本文的文献

1
The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery.PD-L2在接受胃癌根治术患者中的表达及预后预测价值
Future Sci OA. 2025 Dec;11(1):2526993. doi: 10.1080/20565623.2025.2526993. Epub 2025 Jul 2.
2
Sex hormones and immune regulation in ovarian cancer.卵巢癌中的性激素与免疫调节
Discov Oncol. 2024 Dec 31;15(1):849. doi: 10.1007/s12672-024-01675-w.
3
Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1.

本文引用的文献

1
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.树突状细胞的程序性死亡配体1(PD-L1)表达是癌症中T细胞免疫的关键调节因子。
Nat Cancer. 2020 Jul;1(7):681-691. doi: 10.1038/s43018-020-0075-x. Epub 2020 Jun 22.
2
Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.PD-L1和PD-L2在卵巢癌中的表达及预后价值
Transl Cancer Res. 2019 Feb;8(1):111-119. doi: 10.21037/tcr.2019.01.09.
3
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
通过靶向程序性死亡受体配体1(PD-L1)攻击肿瘤细胞和免疫抑制细胞的实体癌导向嵌合抗原受体(CAR)T细胞疗法。
Mol Ther Oncol. 2024 Oct 5;32(4):200891. doi: 10.1016/j.omton.2024.200891. eCollection 2024 Dec 19.
4
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications.癌症风险、预后预测及治疗应用中的可溶性免疫检查点分子
Biomark Res. 2024 Sep 2;12(1):95. doi: 10.1186/s40364-024-00647-0.
5
Release of Exosomal PD-L1 in Bone and Soft Tissue Sarcomas and Its Relationship to Radiotherapy.骨肉瘤和软组织肉瘤中外泌体程序性死亡配体1的释放及其与放疗的关系
Cancers (Basel). 2024 Jul 8;16(13):2489. doi: 10.3390/cancers16132489.
6
Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach.用于卵巢癌患者分层和靶向治疗的免疫相关基因甲基化预后工具,迈向先进的3PM方法。
EPMA J. 2024 Apr 27;15(2):375-404. doi: 10.1007/s13167-024-00359-3. eCollection 2024 Jun.
7
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.胰腺导管腺癌及其前驱病变的空间和表型免疫特征比较
Int J Mol Sci. 2024 Mar 3;25(5):2953. doi: 10.3390/ijms25052953.
8
Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.适体作为卵巢癌潜在治疗工具:进展与挑战
Cancers (Basel). 2023 Nov 6;15(21):5300. doi: 10.3390/cancers15215300.
9
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.解析乳腺癌和卵巢癌干细胞的共同特征及可能的治疗方法。
Int J Mol Sci. 2023 Jun 26;24(13):10683. doi: 10.3390/ijms241310683.
10
Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis.Gal-9 在患有子宫内膜异位症的患者树突状细胞上的表达和 TIM-3/Gal-9 的可溶性形式。
Int J Mol Sci. 2023 Mar 21;24(6):5948. doi: 10.3390/ijms24065948.
阻断 PD-L2 中和对于克服卵巢癌免疫检查点阻断耐药至关重要。
Clin Cancer Res. 2021 Aug 1;27(15):4435-4448. doi: 10.1158/1078-0432.CCR-20-0482. Epub 2021 May 19.
4
Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.游离 CA125 通过与间皮素结合减少 DKK1 的表达并激活 SGK3/FOXO3 通路从而促进卵巢癌细胞迁移和肿瘤转移。
Int J Biol Sci. 2021 Jan 14;17(2):574-588. doi: 10.7150/ijbs.52097. eCollection 2021.
5
Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.PD-L1 在原发性和转移性上皮性卵巢癌中的差异表达及其与临床病理的相关性。
Sci Rep. 2021 Feb 12;11(1):3750. doi: 10.1038/s41598-021-83276-z.
6
Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.程序性死亡-1受体(PD-1)作为卵巢癌患者潜在的预后生物标志物。
Cancer Manag Res. 2020 Oct 7;12:9691-9709. doi: 10.2147/CMAR.S263010. eCollection 2020.
7
Prognostic and Clinical Value of Interleukin 6 and CD45CD14 Inflammatory Cells with PD-L1/PD-L2 Expression in Patients with Different Manifestation of Ovarian Cancer.不同临床表现卵巢癌患者中白细胞介素 6 和 CD45CD14 炎性细胞与 PD-L1/PD-L2 表达的预后和临床价值。
J Immunol Res. 2020 Sep 30;2020:1715064. doi: 10.1155/2020/1715064. eCollection 2020.
8
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade.树突状细胞上的 PD-L1 可减弱 T 细胞的激活,并调节对免疫检查点阻断的反应。
Nat Commun. 2020 Sep 24;11(1):4835. doi: 10.1038/s41467-020-18570-x.
9
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.肝癌患者单核细胞中 PD-L1 和 PD-L2 的表达增加与预后不良相关。
Sci Rep. 2020 Jun 25;10(1):10377. doi: 10.1038/s41598-020-67497-2.
10
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.肿瘤细胞可溶性程序性死亡配体 1 而非 PD-L1 可有效预测软组织肉瘤的转移和预后。
Sci Rep. 2020 Jun 3;10(1):9077. doi: 10.1038/s41598-020-65895-0.